Roche: cancer drug Polivy approved in Canada

(CercleFinance.com) - Roche announced on Thursday that the Canadian health authorities have approved the commercialisation of Polivy in the treatment of adult patients with diffuse large B-cell lymphoma (DLBCL).


The authorisation given by Health Canada concerns the use of the drug in combination with two other anti-cancer drugs - bendamustine and rituximab - in patients who are not eligible for stem cell transplantation and have previously received at least one therapy.

Patients with diffuse large B-cell lymphoma, an aggressive form of non-Hodgkin's lymphoma, usually respond favourably to treatment, although 40% do not recover or relapse, This limits their treatment options and increases the risk of death.


Copyright (c) 2020 CercleFinance.com. All rights reserved.